Azelastine

DRUG4 trials

Sponsors

HAL Allergy B.V., MEDA Pharma GmbH & Co. KG, Shiraz University of Medical Sciences, Sandoz

Conditions

Allergic RhinitisModerate to Severe Allergic Rhinitis/Rhinoconjunctivitis with or without Asthma Induced by House Dust Mite (HDM) AllergySeasonal Allergic Rhinitis

Phase 1

Single Dose Pharmacokinetics of Intranasal Azelastine Delivered by a Fixed Combination With Fluticasone in Comparison to Azelastine Nasal Sprays

CompletedNCT01190852

MEDA Pharma GmbH & Co. KGAllergic Rhinitis

Start: 2010-08-31End: 2010-10-31Updated: 2022-02-07

Phase 3

Prospective, Randomized, Multinational, Multicenter, Double-blind, Placebo and Active Controlled Trial in 4 Parallel-groups of Patients Suffering From Seasonal Allergic Rhinitis

CompletedNCT05311475

SandozSeasonal Allergic Rhinitis

Start: 2022-04-04End: 2023-06-20Updated: 2023-07-11

A Randomized, Double-Blind, Placebo-Controlled, Multi-Centre Study to Assess the Efficacy of PURETHAL Mites Mixture 50,000 AUeq/mL Subcutaneous Immunotherapy in Adult Subjects with Moderate to Severe Allergic Rhinitis/Rhinoconjunctivitis with or without Asthma Induced by House Dust Mite (HDM) Allergy

Active, not recruitingCTIS2023-504942-75-01

HAL Allergy B.V.Moderate to Severe Allergic Rhinitis/Rhinoconjunctivitis with or without Asthma Induced by House Dust Mite (HDM) Allergy

Start: 2024-08-22Target: 582Updated: 2025-12-16

Unknown Phase

Comparison of Montelukast and Azelastine in Treatment of Moderate to Severe Allergic Rhinitis

Shiraz University of Medical SciencesAllergic Rhinitis

Start: 2020-01-16End: 2021-12-15Target: 66Updated: 2020-09-25